• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Wednesday's After-Market Session

    5/1/24 4:31:24 PM ET
    $ALLK
    $ARAY
    $ASXC
    $BFLY
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical/Dental Instruments
    Health Care
    Get the next $ALLK alert in real time by email

    Gainers

    • Pulmonx (NASDAQ:LUNG) shares rose 29.5% to $10.0 during Wednesday's after-market session. The market value of their outstanding shares is at $388.1 million. The company's, Q1 earnings came out today.
    • Butterfly Network (NYSE:BFLY) shares moved upwards by 18.15% to $0.93. The company's market cap stands at $193.5 million. As per the press release, Q1 earnings came out today.
    • Compass Therapeutics (NASDAQ:CMPX) stock rose 11.46% to $1.75. The market value of their outstanding shares is at $240.7 million.
    • Sharps Technology (NASDAQ:STSS) shares increased by 9.2% to $0.27. The market value of their outstanding shares is at $4.2 million.
    • Blueprint Medicines (NASDAQ:BPMC) shares moved upwards by 6.47% to $101.0. The market value of their outstanding shares is at $6.3 billion.
    • Asensus Surgical (AMEX:ASXC) stock rose 6.32% to $0.25. The market value of their outstanding shares is at $69.0 million.

    Losers

    • Envista Holdings (NYSE:NVST) stock decreased by 12.5% to $17.29 during Wednesday's after-market session. The company's market cap stands at $2.9 billion. As per the press release, Q1 earnings came out today.
    • Accuray (NASDAQ:ARAY) shares declined by 12.45% to $1.9. The market value of their outstanding shares is at $188.4 million. As per the news, the Q3 earnings report came out today.
    • Allakos (NASDAQ:ALLK) stock declined by 9.74% to $1.02. The market value of their outstanding shares is at $90.3 million.
    • Psyence Biomedical (NASDAQ:PBM) shares decreased by 7.5% to $1.11. The market value of their outstanding shares is at $14.8 million.
    • Schrodinger (NASDAQ:SDGR) stock fell 7.37% to $23.4. The market value of their outstanding shares is at $1.7 billion. The company's, Q1 earnings came out today.
    • Indaptus Therapeutics (NASDAQ:INDP) stock fell 6.94% to $1.88. The company's market cap stands at $16.0 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $ALLK alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ALLK
    $ARAY
    $ASXC
    $BFLY

    CompanyDatePrice TargetRatingAnalyst
    Compass Therapeutics Inc.
    $CMPX
    2/13/2026$15.00Buy
    Craig Hallum
    Envista Holdings Corporation
    $NVST
    2/6/2026$35.00Market Perform → Outperform
    Leerink Partners
    Compass Therapeutics Inc.
    $CMPX
    1/5/2026Outperform
    William Blair
    Schrodinger Inc.
    $SDGR
    12/15/2025$24.00Neutral → Buy
    BofA Securities
    Envista Holdings Corporation
    $NVST
    12/9/2025$24.00Overweight
    Barclays
    Compass Therapeutics Inc.
    $CMPX
    12/3/2025$10.00Mkt Outperform
    Citizens JMP
    Compass Therapeutics Inc.
    $CMPX
    12/3/2025$10.00Buy
    Canaccord Genuity
    Compass Therapeutics Inc.
    $CMPX
    12/3/2025Overweight
    Cantor Fitzgerald
    More analyst ratings

    $ALLK
    $ARAY
    $ASXC
    $BFLY
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Mayer Steven F bought $30,878 worth of shares (54,875 units at $0.56), increasing direct ownership by 4% to 1,545,620 units (SEC Form 4)

    4 - ACCURAY INC (0001138723) (Issuer)

    2/23/26 4:10:08 PM ET
    $ARAY
    Medical/Dental Instruments
    Health Care

    Director Mayer Steven F bought $103,797 worth of shares (195,125 units at $0.53), increasing direct ownership by 15% to 1,490,745 units (SEC Form 4)

    4 - ACCURAY INC (0001138723) (Issuer)

    2/20/26 4:10:06 PM ET
    $ARAY
    Medical/Dental Instruments
    Health Care

    Director Phanstiel S. Louise bought $571,160 worth of shares (185,261 units at $3.08) (SEC Form 4)

    4 - Butterfly Network, Inc. (0001804176) (Issuer)

    12/17/25 4:10:13 PM ET
    $BFLY
    Medical Electronics
    Health Care

    $ALLK
    $ARAY
    $ASXC
    $BFLY
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Accuray Appoints Paul Miele as Senior Vice President and Chief Commercial Officer

    MADISON, Wis., April 6, 2026 /PRNewswire/ -- Accuray Incorporated (NASDAQ:ARAY), a leading provider of radiation therapy systems for cancer treatment, today announced the appointment of Paul Miele as Senior Vice President and Chief Commercial Officer, effective April 6, 2026. Miele will join Accuray's executive leadership team and lead the company's global commercial organization as Accuray continues to advance its transformation and strengthen execution across its portfolio. "Paul brings deep global commercial leadership experience and a strong track record of driving transform

    4/6/26 9:00:00 AM ET
    $ARAY
    Medical/Dental Instruments
    Health Care

    Sharps Technology Reports 2025 Year-End Results and Highlights Continued Execution of Solana Treasury Strategy

    Over 2 Million SOL Held with Approximately 95% Staked at ~7% Gross Annualized YieldTotal Assets of $269.1 Million, Up from $7.3 Million at Year-End 2024Expanded Solana Ecosystem Partnerships Including Coinbase, Crypto.com, BitGo, and Jupiter NEW YORK, April 06, 2026 (GLOBE NEWSWIRE) -- Sharps Technology, Inc. ("Sharps" or the "Company"), a medical device sales and distribution company that has adopted a Solana-based digital asset treasury strategy, has announced financial results for the year ended December 31, 2025, and provided an update on the continued execution of its treasury and infrastructure strategy. The Company entered 2025 as a capital-constrained medical device manuf

    4/6/26 7:00:00 AM ET
    $STSS
    Medical/Dental Instruments
    Health Care

    Butterfly Network Secures First FDA Clearance for Blind Sweep Ultrasound AI Tool, Marking a Major Stride for Women's Health

    The new AI-powered tool determines how far along a pregnancy is in minutes—providing critical information to guide timely care and help reduce maternal and fetal mortality worldwide. Butterfly Network, Inc. ("Butterfly," "the Company") (NYSE:BFLY), a pioneer and leader in semiconductor-based ultrasound devices, programmable cloud software and AI, today announced it has received clearance from the U.S. Food and Drug Administration (FDA) for a fully automated Gestational Age (GA) Tool integrated into its handheld ultrasound solution. This marks the first FDA-cleared blind-sweep ultrasound AI tool for estimating gestational age. This press release features multimedia. View the full release

    3/30/26 8:00:00 AM ET
    $BFLY
    Medical Electronics
    Health Care

    $ALLK
    $ARAY
    $ASXC
    $BFLY
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Craig Hallum initiated coverage on Compass Therapeutics with a new price target

    Craig Hallum initiated coverage of Compass Therapeutics with a rating of Buy and set a new price target of $15.00

    2/13/26 8:35:30 AM ET
    $CMPX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Envista upgraded by Leerink Partners with a new price target

    Leerink Partners upgraded Envista from Market Perform to Outperform and set a new price target of $35.00

    2/6/26 8:05:48 AM ET
    $NVST
    Medical/Dental Instruments
    Health Care

    William Blair initiated coverage on Compass Therapeutics

    William Blair initiated coverage of Compass Therapeutics with a rating of Outperform

    1/5/26 8:57:39 AM ET
    $CMPX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ALLK
    $ARAY
    $ASXC
    $BFLY
    SEC Filings

    View All

    Accuray Incorporated filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

    8-K - ACCURAY INC (0001138723) (Filer)

    4/7/26 9:00:20 AM ET
    $ARAY
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Indaptus Therapeutics Inc.

    SCHEDULE 13G/A - Indaptus Therapeutics, Inc. (0001857044) (Subject)

    4/6/26 4:40:14 PM ET
    $INDP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Accuray Incorporated filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - ACCURAY INC (0001138723) (Filer)

    4/6/26 9:00:13 AM ET
    $ARAY
    Medical/Dental Instruments
    Health Care

    $ALLK
    $ARAY
    $ASXC
    $BFLY
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by new insider Yao Yun

    3 - Indaptus Therapeutics, Inc. (0001857044) (Issuer)

    4/2/26 7:18:19 PM ET
    $INDP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by new insider Sino Lion Ventures Ltd

    3 - Indaptus Therapeutics, Inc. (0001857044) (Issuer)

    4/2/26 7:16:54 PM ET
    $INDP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by new insider Dai Junyi

    3 - Indaptus Therapeutics, Inc. (0001857044) (Issuer)

    4/2/26 7:15:30 PM ET
    $INDP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALLK
    $ARAY
    $ASXC
    $BFLY
    Leadership Updates

    Live Leadership Updates

    View All

    Accuray Appoints Paul Miele as Senior Vice President and Chief Commercial Officer

    MADISON, Wis., April 6, 2026 /PRNewswire/ -- Accuray Incorporated (NASDAQ:ARAY), a leading provider of radiation therapy systems for cancer treatment, today announced the appointment of Paul Miele as Senior Vice President and Chief Commercial Officer, effective April 6, 2026. Miele will join Accuray's executive leadership team and lead the company's global commercial organization as Accuray continues to advance its transformation and strengthen execution across its portfolio. "Paul brings deep global commercial leadership experience and a strong track record of driving transform

    4/6/26 9:00:00 AM ET
    $ARAY
    Medical/Dental Instruments
    Health Care

    Corporate Update: Psyence BioMed Advances Vertically Integrated Pharmaceutical Platform Following PsyLabs Export Milestone

    NEW YORK, March 11, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (NASDAQ:PBM) ("Psyence BioMed" or the "Company") today reinforced how its strategic investment in PsyLabs strengthens its control over pharmaceutical-grade manufacturing and commercial supply chain infrastructure – a critical differentiator in the rapidly expanding psychedelic pharmaceutical sector. Through its investment in PsyLabs, Psyence BioMed has secured: A licensed, owned, and debt-free production operation.Source-level ibogaine supply.Natural psilocybin supply.GMP-compliant manufacturing capabilities.Intellectual property protection.Integrated analytical and chemistry laboratory infrastructure.A capital structur

    3/11/26 9:15:00 AM ET
    $PBM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Butterfly Network Appoints David Horsley as Senior Vice President, Innovation – Butterfly Embedded™

    Chirp Microsystems Co-Founder Joins Butterfly to Advance its Ultrasound-on-Chip™ Platform Strategy Butterfly Network, Inc. (NYSE:BFLY) ("Butterfly"), a pioneer and leader in semiconductor-based ultrasound devices, programmable cloud software and AI, today announced the appointment of David Horsley, Ph.D. as Senior Vice President of Innovation – Butterfly Embedded™ to scale its Ultrasound-on-Chip™ co-development and licensing initiative. In this role, Dr. Horsley will lead strategy and go-to-market for Butterfly Embedded, overseeing new product development, partnerships, and commercialization efforts. Butterfly Embedded is focused on extending the reach of the company's proprietary semic

    3/10/26 8:05:00 AM ET
    $BFLY
    Medical Electronics
    Health Care

    $ALLK
    $ARAY
    $ASXC
    $BFLY
    Financials

    Live finance-specific insights

    View All

    Pulmonx Reports Fourth Quarter and Full Year 2025 Financial Results

    REDWOOD CITY, Calif., March 04, 2026 (GLOBE NEWSWIRE) -- Pulmonx Corporation (NASDAQ:LUNG) ("Pulmonx" or the "Company"), a global leader in minimally invasive treatments for lung disease, today reported financial results for the fourth quarter and full year ended December 31, 2025. Recent Highlights Delivered $90.5 million in worldwide revenue for the full year of 2025, an 8% increase over the prior year and an increase of 7% on a constant currency basisAchieved worldwide revenue of $22.6 million for the fourth quarter of 2025, a 5% decrease over the same period last year and a decrease of 7% on a constant currency basisRealized gross margin of 78% in the fourth quarter of 2025 and 7

    3/4/26 4:06:00 PM ET
    $LUNG
    Medical/Dental Instruments
    Health Care

    Butterfly Network Reports Fourth Quarter 2025 Financial Results

    Delivered Record Annual and Quarterly Revenue Reported quarterly record Revenue of $31.5 million in Q4, representing 41% YoY growth Generated positive net cash flow of $6.3 million in Q4 and lowest annual cash usage in company history Midjourney partnership contributed $6.8 million of revenue in Q4, advancing Butterfly Embedded™ platform strategy Butterfly Network, Inc. (NYSE:BFLY) ("Butterfly" or the "Company"), a digital health company transforming care with semiconductor chip-based ultrasound devices, software and AI, today announced financial results for the fourth quarter and year ended December 31, 2025, and provided a business update. Joseph DeVivo, Butterfly's Presiden

    2/26/26 6:30:00 AM ET
    $BFLY
    Medical Electronics
    Health Care

    Schrödinger Reports Fourth Quarter and Full-Year 2025 Financial Results

    2025 Total Revenue of $256 Million 2025 Software Revenue of $200 Million; 2025 Software ACV of $198 Million Strong Balance Sheet Supports Path to Positive Adjusted EBITDA by Year-End 2028 Accelerating Transition to Ratable, Hosted Software Revenue Schrödinger, Inc. (NASDAQ:SDGR) today announced financial results for the fourth quarter and full-year ended December 31, 2025, and provided its 2026 outlook and 2028 financial objectives. "Schrödinger's performance in 2025, marked by 23% total revenue growth and 11% software revenue growth, is a testament to the resilience of our business and the unique value we provide," said Ramy Farid, Ph.D., chief executive officer of Schrödinger. "

    2/25/26 4:05:00 PM ET
    $SDGR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALLK
    $ARAY
    $ASXC
    $BFLY
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Psyence Biomedical Ltd.

    SC 13G - PSYENCE BIOMEDICAL LTD. (0001985062) (Subject)

    12/13/24 9:16:01 AM ET
    $PBM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Psyence Biomedical Ltd.

    SC 13G/A - PSYENCE BIOMEDICAL LTD. (0001985062) (Subject)

    12/9/24 1:36:43 PM ET
    $PBM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Psyence Biomedical Ltd.

    SC 13G/A - PSYENCE BIOMEDICAL LTD. (0001985062) (Subject)

    12/4/24 4:38:27 PM ET
    $PBM
    Biotechnology: Pharmaceutical Preparations
    Health Care